Several anti-PD-1/PD-L1 antibodies, including pembrolizumab, nivolumab, and atezolizumab, have been approved for the treatment of advanced NSCLC after remarkable improvement in median overall NSCLC patient survival was demonstrated in clinical trials [11,12]. Here, CD274 is linked to non-small cell lung carcinoma.